Business News | Jagsonpal Pharmaceuticals strengthens its market position with the acquisition of Yash Pharma

PNN

Mumbai (Maharashtra) (India), June 27: Jagsonpal Pharmaceuticals has announced the acquisition of Yash Pharma’s Indian and Bhutanese businesses. The transaction, facilitated by boutique investment firm Growthally Advisors, is expected to not only expand Jagsonpal’s therapeutic reach but also significantly improve its market position.

Read also | Google Translate adds 110 new languages, including Cantonese, Tamazight and Nko, spoken by over 614 million people.

This acquisition is even more significant as two companies with complementary strengths are combining. Jagsonpal has already built a 60-year legacy with its strong presence in gynecology and orthopedics. Now this is further strengthened as Yash Pharma’s well-established portfolio of 33 dermatology and pediatric brands becomes part of their offering. This strategic move not only diversifies Jagsonpal’s product offering but also enables them to establish their presence in a new Rs 20,000-crore market segment (Source: IQVIA) with significant growth opportunities available.

As stated in Jagsonpal’s investor presentation, “This acquisition is a perfect recipe for Jagsonpal. Yash Pharma’s strengths in dermatology and pediatrics can now be leveraged to align with our long-term growth goals. Now, as our portfolio expands to include new customer segments, the company is poised to significantly strengthen our market position.”

Read also | IMD weather forecast for Delhi: Heavy to very heavy rainfall is likely in the national capital on June 29 and 30.

Development Advisors: Navigating This Strategic Growth Course

Growthally Advisors Pvt. Ltd., a boutique investment firm with a strong understanding and experience in the Indian pharmaceutical and healthcare markets, helped navigate this seemingly complex transaction by leveraging its innate M&A experience. The shared vision of delivering sustainable and profitable long-term growth aligned perfectly with Jagsonpal’s needs.

Bhupinder Garg, Managing Director, Growthally Advisors, states, “We are proud to have facilitated this mutually beneficial partnership. We have always helped emerging corporates in the Indian pharmaceutical and healthcare industry unlock their long-term goals through innovative solutions that optimize their growth trajectory. We believe this transaction is a great example of how strategic acquisitions can deliver benefits to all stakeholders.”

Ravi Jaisalmeria, Director, Growthally Advisors added: “GrowthAlly does not limit its expertise to M&A advisory. They offer a comprehensive suite of services that includes private capital, debt syndication, startup fundraising, corporate leasing and CFO services. With a holistic approach to supporting companies throughout their growth journey, clients receive both the strategic guidance and financial advice needed to leverage emerging opportunities to achieve their long-term goals.

Shekhar Bhuwania, Director, GrowthAlly Advisors further stated, “The Indian pharmaceutical sector in particular is set to grow at a significant pace. Strategically planned collaborations and acquisitions will prove to be a key driver in unlocking the immense potential of this industry. This is why we remain committed to always partnering with companies that need help in navigating this exciting journey in their ultimate pursuit of sustainable growth.

Mergers and Acquisitions: Their Role in Driving India’s Growth Story

As strategic partnerships and mergers are becoming more common in the vast Indian pharmaceutical industry, it also requires extreme caution in the entire process. As pharmaceutical companies prepare to chart their course in an increasingly competitive market, a boutique investment firm like Growthally Advisors plays an important role. This is due to their experience in identifying and executing transactions that drive long-term value creation.

Mergers and Acquisitions: Driving Growth in the Indian Pharmaceutical Sector

Mergers and acquisitions have become common in India’s rapidly growing pharmaceutical sector, which is expected to exceed $130 billion by 2030. In the first quarter of 2024 alone, 24 M&A transactions with a total value of USD 456.3 million have already been finalized (source: GlobalData transaction database). This further highlights the collective desire of Indian pharma companies to diversify their portfolios, enter new markets and gain access to innovative technologies.

The benefits are numerous: combining R&D capabilities can accelerate drug development while providing access to new technologies. Other benefits highlighted include increased market share, improved financial performance, as well as generating synergies through streamlined operations.

However, mergers and acquisitions in the pharmaceutical industry come with challenges. Integrating diverse company cultures and systems can be disruptive. Regulatory hurdles, including antitrust laws, can delay or derail the entire process. Additionally, pipeline risks and potential reputational damage can pose significant obstacles.

(ADVERTISING DISCLAIMER: The above press release was provided by PNN. ANI is not responsible for its content)

(This is an unedited and auto-generated story from a Syndicated News channel, LatestLY staff may not have modified or edited the content content)